ERBB2 and gastric cancer: The anti-proliferative effects of trastuzumab in these cells were comparable to those observed in HER2-positive gastric cancer cell lines, NCI-N87 and SNU-216, and a HER2-positive breast cancer cell line, SK-BR-3 [13].